Interleukin-1-alpha - Otsuka
Alternative Names: OCT 7000; OCT 8000Latest Information Update: 24 Oct 2021
At a glance
- Originator Otsuka Pharmaceutical
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 1 alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Preleukaemia
Most Recent Events
- 22 Jan 2001 No-Development-Reported for Cancer in Japan (Unknown route)
- 22 Jan 2001 No-Development-Reported for Preleukaemia in Japan (Unknown route)
- 30 Nov 1995 Phase-II clinical trials for Preleukaemia in Japan (Unknown route)